64-77-7
64-77-7
Chemical Structure
Tolbutamide
- CAS No.: 64-77-7
- Formula:C12H18N2O3S
- Molecular Weight:270.35
IUPAC Name: N-(butylcarbamoyl)-4-methylbenzenesulfonamide
InChIKey: JLRGJRBPOGGCBT-UHFFFAOYSA-N
SMILES: O=S(C1=CC=C(C)C=C1)(NC(NCCCC)=O)=O
Biological Activity: Tolbutamide is an orally active KATP inhibitor. Tolbutamide inhibits cell proliferation, stimulates exocytosis of glucagon and reduces fetal lethality of mice. Tolbutamide can be used in the research of diabete[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tolbutamide | 99.69% | Tolbutamide is an orally active KATP inhibitor. Tolbutamide inhibits cell proliferation, stimulates exocytosis of glucagon and reduces fetal lethality of mice. Tolbutamide can be used in the research of diabete. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tolbutamide (Standard) | 99.99% | Tolbutamide (Standard) is the analytical standard of Tolbutamide. This product is intended for research and analytical applications. Tolbutamide is an orally active KATP inhibitor. Tolbutamide inhibits cell proliferation, stimulates exocytosis of glucagon and reduces fetal lethality of mice. Tolbutamide can be used in the research of diabete. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tolbutamide-13C | Tolbutamide-13C is the 13C-labeled Tolbutamide. Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic agent. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tolbutamide-d9 | 99.0% | Tolbutamide-d9 is the deuterium labeled Tolbutamide. Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sánchez‐Alvarez R, et al. Tolbutamide reduces glioma cell proliferation by increasing connexin43, which promotes the up‐regulation of p21 and p27 and subsequent changes in retinoblastoma phosphorylation [J]. Glia, 2006, 54(2): 125-134. [Content Brief]
- [2]. Hœy M, et al. Tolbutamide stimulates exocytosis of glucagon by inhibition of a mitochondrial‐like ATP‐sensitive K+ (KATP) conductance in rat pancreatic A‐cells [J]. The Journal of Physiology, 2000, 527(1): 109-120. [Content Brief]
- [3]. Williams A J K, et al. Tolbutamide reduces the incidence of diabetes mellitus, but not insulitis, in the non-obese-diabetic mouse [J]. Diabetologia, 1993, 36: 487-492. [Content Brief]
- [4]. Belisle R J, et al. Tolbutamide treatment of pregnant mice: repeated administration reduces fetal lethality [J]. Teratology, 1976, 13(1): 65-70. [Content Brief]
